Tenofovir Disoproxsil Fumarate in the Treatment of AIDS

Tenofovir Disoproxsil Fumarate in the Treatment of AIDS

Tenofovir disoproxil fumarate is an antiviral drug used against HIV (Human Immunodeficiency Virus) and hepatitis B (HBV) viruses in adults. It is an acyclic nucleoside phosphonate diester analogue of adenosine monophosphate. Tenofovir is a nucleotide reverse transcriptase inhibitor and it shows acti...

Full description

Bibliographic Details
Main Authors:	Kubra Kurt, Lale Donbak, Ahmet Kayraldiz
Format:	Article
Language:	Turkish
Published:	Cukurova University Faculty of Medicine 2015-03-01
Series:	Arsiv Kaynak Tarama Dergisi
Subjects:	Tenofovir Disoproxil Fumarate Nucleotide reverse transcriptase inhibitors HIV HBV
Online Access:	http://www.scopemed.org/fulltextpdf.php?mno=166511

Similar Items

Evaluation of genotoxic activity of tenofovir disoproxil fumarate in human peripheral lymphocytes
by: Kubra Kurt, et al.
Published: (2016-06-01)

Renal function change after switching tenofovir disoproxil fumarate for tenofovir alafenamide in the HIV-positive patients of a metropolitan sexual health service
by: Dane Turner, et al.
Published: (2019-12-01)

Changing trends in lipid profile and biomarkers of renal function and bone metabolism before and after switching from tenofovir disoproxil fumarate to tenofovir alafenamide: a prospective observational study
by: Mahoko Ikeda, et al.
Published: (2021-05-01)

Prevalence of Nephrotoxicity in HIV Patients Treated with Tenofovir Disoproxil Fumarate: A Single-center Observational Study
by: Kowthar Salman Hassan, et al.
Published: (2019-05-01)

The genotoxicity of Tenofovir disoproxil fumarate in HBV-infected patients
by: Selcen Korkmaz, et al.
Published: (2018-09-01)

Real-world impact of switching from tenofovir disoproxil fumarate to tenofovir alafenamide
by: Sarah M Michienzi, et al.
Published: (2021-07-01)

Renal Dysfunction and Tubulopathy Induced by High-Dose Tenofovir Disoproxil Fumarate in C57BL/6 Mice
by: Eungyeong Jang, et al.
Published: (2020-10-01)

Method development and validation for multi-component analysis of lamivudine & tenofovir disoproxil fumarate in bulk drug by UV-visible spectrophotometer & RP-HPLC
by: Shweta Sharma, et al.
Published: (2020-11-01)

Bone outcomes in virally suppressed youth with HIV switching to tenofovir disoproxil fumarate
by: Kate Braithwaite, et al.
Published: (2021-08-01)

Reverse phase-liquid chromatography assisted protocol for simultaneous determination of lamivudine and tenofovir disoproxil fumarate in combined medication used to control HIV infection: an investigative approach
by: Vaibhav S. Adhao, et al.
Published: (2021-04-01)

Latest progress in treatment of chronic hepatitis B with tenofovir disoproxil fumarate
by: ZHANG Yue
Published: (2015-04-01)

Prevalence and factors associated with renal dysfunction in patients on tenofovir disoproxil fumarate-based antiretroviral regimens for HIV infection in Southern India
by: Nagalingeswaran Kumarasamy, et al.
Published: (2018-01-01)

Rates and predictors of switching to tenofovir alafenamide-containing ART in a nationwide cohort
by: Bernard Surial, et al.
Published: (2019-10-01)

Tenofovir-associated renal toxicity in a cohort of HIV infected patients in Ghana
by: Edmund T. Nartey, et al.
Published: (2019-07-01)

Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B
by: Juan Li, et al.
Published: (2021-06-01)

Establishment of HK-2 Cells as a Relevant Model to Study Tenofovir-Induced Cytotoxicity
by: Rachel A. Murphy, et al.
Published: (2017-03-01)

Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy
by: Ogawa E, et al.
Published: (2017-11-01)

Dyslipidemia and Associated Factors in Tenofovir Disoproxil Fumarate-Based Regimen Among Human Immunodeficiency Virus-Infected Ethiopian Patients: A Hospital-Based Observational Prospective Cohort Study
by: Yazie TS
Published: (2020-12-01)

The Occurrence of rtA194T Mutant After Long-Term Lamivudine Monotherapy Remains Sensitive to Tenofovir Disoproxil Fumarate: A Case Report
by: Li J, et al.
Published: (2021-03-01)

Concurrent estimation of lamivudine, tenofovir disoproxil fumarate, and efavirenz in blended mixture and triple combination tablet formulation by a new stability indicating RP-HPLC method
by: Ramreddy Godela, et al.
Published: (2021-04-01)

Tenofovir Alafenamide Rescues Renal Tubules in Patients with Chronic Hepatitis B
by: Tomoya Sano, et al.
Published: (2021-03-01)

Impact of dosing strategies on plasma concentrations of tenofovir: Implications in HIV pre-exposure prophylaxis in China
by: Jingchuan Shang, et al.
Published: (2021-09-01)

Chronic Kidney Disease and Associated Factors Among HIV Infected Patients Taking Tenofovir Disoproxil Fumarate Based Regimen in Ethiopia: A Hospital-Based Cross-Sectional Study
by: Belete AM, et al.
Published: (2021-03-01)

Efficacy of tenofovir alafenamide in treatment of hepatitis B virus: A meta-analysis and non-inferiority evaluation
by: Qiu-Ran Wang, et al.
Published: (2021-06-01)

Early Start Of Tenofovir Treatment Achieves Better Viral Suppression In Pregnant Women With A High HBV Viral Load: A Real-World Prospective Study
by: Gao F, et al.
Published: (2019-11-01)

QbD based approach for optimization of Tenofovir disoproxil fumarate loaded liquid crystal precursor with improved permeability
by: Sharvil Patil, et al.
Published: (2017-11-01)

Tenofovir Is Superior to Entecavir on Tertiary Prevention for BCLC Stage 0/A Hepatocellular Carcinoma after Curative Resection
by: Ming-Chao Tsai, et al.
Published: (2021-09-01)

Assessment of urinary cystatin C levels in HIV-1-infected patients with preserved kidney function
by: Aleksandra Szymczak, et al.
Published: (2018-11-01)

Formulation and evaluation of polymeric micelles for improved oral delivery of tenofovir disoproxil fumarate and zidovudine using poly-lactic-co-glycolic acid nanoparticles
by: Tenghe, Lovette Asobo
Published: (2019)

Compare with safety and efficacy of entecavir and adefovir dipivoxil combination therapy and tenofovir disoproxil fumarate monotherapy for chronic hepatitis B patient with adefovir-resistant
by: Ming-Chun Lai, et al.
Published: (2020-01-01)

Distinctive HBV Replication Capacity and Susceptibility to Tenofovir Induced by a Polymerase Point Mutation in Hepatoma Cell Lines and Primary Human Hepatocytes
by: Ah Ram Lee, et al.
Published: (2021-02-01)

Tenofovir Disoproxil Fumarate-Associated Renal Dysfunction Among Adult People Living with HIV at the University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia, 2019: A Comparative Retrospective Cohort Study
by: Debeb SG, et al.
Published: (2021-05-01)

Estudo da toxicidade genética de efavirenz (EFV) e fumarato de tenofovir desoproxila (TDF) em células somáticas de drosophila melanogaster
by: Moraes Filho, Aroldo Vieira de
Published: (2017)

Kidney dysfunction associated with tenofovir exposure in human immunodeficiency virus-1-infected Taiwanese patients
by: Yu-Shan Huang, et al.
Published: (2017-10-01)

Hepatitis B virus (HBV) viral load, liver and renal function in adults treated with tenofovir disoproxil fumarate (TDF) vs. untreated: a retrospective longitudinal UK cohort study
by: Tingyan Wang, et al.
Published: (2021-06-01)

Tenofovir Disoproxil Fumarate Is Superior to Entecavir in Reducing Hepatitis B Surface Antigen for Chronic Hepatitis B in China: 2-Year Comprehensive Comparative Result of a Matched Comparative Study
by: Sisi Yang, et al.
Published: (2021-03-01)

Efficacy and Safety of Tenofovir and Lamivudine in Combination with Efavirenz in Patients Co-infected with Human Immunodeficiency Virus and Hepatitis B Virus in China
by: Ya-Song Wu, et al.
Published: (2016-01-01)

Impact of Tenofovir Disoproxil‐Induced Fanconi Syndrome on Bone Material Quality: A Case Report
by: Benjamin Hadzimuratovic, et al.
Published: (2021-06-01)

Entecavir administration to pregnant Japanese woman with chronic hepatitis B and hepatocellular carcinoma: A case report
by: Toshihiko Kakiuchi, et al.
Published: (2021-03-01)

Development and validation of a stability-indicating lc method for the determination of tenofovir disoproxil fumarate in pharmaceutical formulation
by: Shweta Havele, et al.
Published: (2012-12-01)